TARGT Absolute Pro

Giving CGP an edge with AI-based Insights

Unlocking the potential of AI-driven CGP analysis on whole-exome DNA and RNA from FFPE block combined with Comprehensive Liquid Biopsy Profiling.

4baseCare, in collaboration with Cellworks, a U.S.-based company, has brought AI-driven Personalized Cancer Care to India with TARGT Absolute Pro, an advanced AI/ML Biosimulation Approach which analyzes ~20,000 genes that provide a comprehensive report based on whole-exome DNA and RNA profiling to reveal the best therapy combinations with genomic biomarkers.

It utilizes Cellworks proprietory Therapy Response Index (TRI) & Pathway Analysis algorithm within Cellworks Venturaä report to guide oncologists in selecting the most efficacious treatment strategy for improved clinical outcomes.

An integrated NGS analysis of Tissue (Solid biopsy), ctDNA (Liquid biopsy), and Whole blood (gDNA) allows identifying true somatic mutations and queries both tissue DNA/RNA and ctDNA in parallel to gain Optimal Disease Resolution leading to better clinical decision-making. It helps in truly personalizing cancer treatment in solid cancer management.

Benefits of TARGT Absolute Pro Gene Panel Testing

Therapy prediction

This gene panel generates an in-depth report based on the whole-exome DNA and RNA profiling by leveraging AI and machine learning algorithms. This report includes the Cellworks proprietary Therapy Response Index (TRI) and Pathway Analysis, which helps oncologists predict and assess the patient’s response to different therapies.

Solid and liquid biopsy integration

This comprehensive approach identifies true somatic mutations and enables parallel tissue DNA/RNA and ctDNA analysis. As a result, it facilitates optimal disease resolution and improves clinical decision-making.

Personalized treatment selection

By combining the insights from comprehensive genomic analysis and therapy prediction, this gene panel empowers oncologists to personalize cancer treatment plans. The information provided in the report helps guide clinicians in selecting the most appropriate therapies and combinations tailored to each patient’s unique genomic profile.

Improved clinical outcomes

By providing oncologists with more accurate and detailed information about the patient’s tumor characteristics and predicted therapy responses, it enhances treatment decision-making and facilitates targeted therapy selection that leads to improved treatment efficacy, reduced adverse effects, and better patient outcomes.

Why Choose 4baseCare's TARGT Absolute Pro Cancer Gene Panel?

Comprehensive Analysis

Our Cancer Gene Panel thoroughly assesses clinically relevant genes, ensuring accurate and reliable results.

Advanced Technology

We utilize cutting-edge genomic sequencing technologies to deliver precise and detailed genetic information.

Expert Team

Our team of experienced genetic counselors and healthcare professionals will guide you through the testing process, answer your questions, and help you understand the implications of the results.

Somatic Test